{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:13:17Z","timestamp":1788801197431,"version":"build-2803163510"},"reference-count":39,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Langerhans cell histiocytosis (LCH) confined to the skeleton has excellent survival, yet optimal management of multifocal bone disease and lesions at traditionally defined \u201cspecial sites\u201d remains uncertain due to limited prospective data. We report prospective results from an international pilot trial embedded within the Histiocyte Society LCH-III study (2001-2008) evaluating 6 months of vinblastine-prednisolone in children with single-system skeletal LCH. Among 455 enrolled patients, 381 were evaluable. Early response at week 6 was achieved in 83% of cases. Five-year overall survival was 100%, and event-free survival (EFS) was 71%. Multifocal bone lesions (MFB) were the dominant predictor of relapse (5-year EFS: 63% vs 87% without MFB; P&amp;lt; .001), whereas isolated central nervous system (CNS)-risk skeletal lesions did not independently affect EFS. In contrast, the cumulative incidence of central diabetes insipidus at 5 years was 5% overall but was significantly higher in patients with CNS-risk lesions, particularly when combined with MFB. These prospective data demonstrate that in single-system skeletal LCH, disease extent and lesion location confer distinct risks, with skeletal multiplicity determining relapse propensity, and anatomic location determining the risk of permanent endocrine sequelae. This study provides a prospective international benchmark for systemic therapy and supports risk-adapted treatment strategies that minimize long-term morbidity while avoiding unnecessary treatment escalation. This trial was registered at www.ClinicalTrials.gov as NCT00276757.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020075","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:22:54Z","timestamp":1778577774000},"page":"4776-4785","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis"],"prefix":"10.1182","volume":"10","author":[{"given":"Itziar","family":"Astigarraga","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Hospital Universitario Cruces, Osakidetza, Bizkaia UPV\/EHU, Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Arnardottir","sequence":"additional","affiliation":[{"name":"2Children\u2019s Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Abla","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-6671","authenticated-orcid":false,"given":"Maurizio","family":"Arico","sequence":"additional","affiliation":[{"name":"4Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Braier","sequence":"additional","affiliation":[{"name":"5Hospital Nacional de Pediatria J. Garrahan, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-146X","authenticated-orcid":false,"given":"Jean","family":"Donadieu","sequence":"additional","affiliation":[{"name":"6Reference Centre for Histiocytosis at H\u00f4pital Armand-Trousseau, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Grois","sequence":"additional","affiliation":[{"name":"7Fuchsthal Kindermedizin 1090, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0629-2126","authenticated-orcid":false,"given":"Jan-Inge","family":"Henter","sequence":"additional","affiliation":[{"name":"8Childhood Cancer Research Unit, Department of Women\u2019s and Children\u2019s Health, Karolinska Institute, Stockholm, Sweden"},{"name":"9Pediatric Oncology, Astrid Lindgren Children\u2019s Hospital, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2484-1456","authenticated-orcid":false,"given":"Stephan","family":"Ladisch","sequence":"additional","affiliation":[{"name":"10Children\u2019s National Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6022-3439","authenticated-orcid":false,"given":"Thomas","family":"Lehrnbecher","sequence":"additional","affiliation":[{"name":"11Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe University, Frankfurt\/Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-6263","authenticated-orcid":false,"given":"Kenneth","family":"McClain","sequence":"additional","affiliation":[{"name":"12Texas Children\u2019s Cancer and Hematology Centers, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanta","family":"Nanduri","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics, Watford General Hospital, Watford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-8946","authenticated-orcid":false,"given":"Carlos","family":"Rodriguez-Galindo","sequence":"additional","affiliation":[{"name":"14Department of Global Pediatrics and Department of Oncology, St Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-9812","authenticated-orcid":false,"given":"Elena","family":"Sieni","sequence":"additional","affiliation":[{"name":"15Pediatric Hematology\/Oncology Department, Meyer Children\u2019s University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Weitzman","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"P\u00f6tschger","sequence":"additional","affiliation":[{"name":"2Children\u2019s Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6471-8423","authenticated-orcid":false,"given":"Milen","family":"Minkov","sequence":"additional","affiliation":[{"name":"2Children\u2019s Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria"},{"name":"16Center of Child Health, Growth, and Development, Faculty of Medicine, Sigmund Freud University, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"8","key":"2026071409581209700_bib1","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.4049\/jimmunol.0902336","article-title":"Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells","volume":"184","author":"Allen","year":"2010","journal-title":"J Immunol"},{"issue":"11","key":"2026071409581209700_bib2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2026071409581209700_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1084\/jem.2013097701202015c","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"212","author":"Berres","year":"2015","journal-title":"J Exp Med"},{"issue":"19","key":"2026071409581209700_bib4","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2026071409581209700_bib5","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2026071409581209700_bib6","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1182\/blood-2012-02-410241","article-title":"Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells","volume":"120","author":"Hutter","year":"2012","journal-title":"Blood"},{"key":"2026071409581209700_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/ITT.S91058","article-title":"Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies","volume":"5","author":"Hutter","year":"2016","journal-title":"Immunotargets Ther"},{"issue":"5","key":"2026071409581209700_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1067\/mpd.2001.111331","article-title":"A randomized trial of treatment for multisystem Langerhans' cell histiocytosis","volume":"138","author":"Gadner","year":"2001","journal-title":"J Pediatr"},{"issue":"5","key":"2026071409581209700_bib9","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2026071409581209700_bib10","first-page":"57","article-title":"Prognostic factors in histiocytosis X","volume":"3","author":"Lahey","year":"1981","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"2","key":"2026071409581209700_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mpo.1178","article-title":"Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study","volume":"37","author":"Titgemeyer","year":"2001","journal-title":"Med Pediatr Oncol"},{"issue":"25","key":"2026071409581209700_bib12","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2026071409581209700_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.20425","article-title":"Risk factors for diabetes insipidus in Langerhans cell histiocytosis","volume":"46","author":"Grois","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026071409581209700_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mpo.2950230207","article-title":"LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society","volume":"23","author":"Ladisch","year":"1994","journal-title":"Med Pediatr Oncol"},{"issue":"2","key":"2026071409581209700_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0889-8588(05)70513-X","article-title":"Current therapy for Langerhans cell histiocytosis","volume":"12","author":"Broadbent","year":"1998","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2026071409581209700_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0962280209105020","article-title":"Pseudo-observations in survival analysis","volume":"19","author":"Andersen","year":"2010","journal-title":"Stat Methods Med Res"},{"key":"2026071409581209700_bib17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of k-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"The Ann Stat"},{"issue":"2","key":"2026071409581209700_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"4","key":"2026071409581209700_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/mpo.2950180407","article-title":"Histiocytosis X in bone only","volume":"18","author":"Berry","year":"1990","journal-title":"Med Pediatr Oncol"},{"issue":"4","key":"2026071409581209700_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01241398-199107000-00009","article-title":"Bone lesions in histiocytosis X","volume":"11","author":"Bollini","year":"1991","journal-title":"J Pediatr Orthop"},{"issue":"2","key":"2026071409581209700_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/000992289303200213","article-title":"Bone lesions in Langerhans cell histiocytosis","volume":"32","author":"Fiorillo","year":"1993","journal-title":"Clin Pediatr"},{"issue":"12","key":"2026071409581209700_bib22","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/1097-0142(19951215)76:12<2471::AID-CNCR2820761211>3.0.CO;2-Z","article-title":"Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases","volume":"76","author":"Kilpatrick","year":"1995","journal-title":"Cancer"},{"issue":"3","key":"2026071409581209700_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14656566.2018.1429405","article-title":"An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy","volume":"19","author":"Minkov","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2026071409581209700_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mpo.2950250204","article-title":"Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis","volume":"25","author":"Womer","year":"1995","journal-title":"Med Pediatr Oncol"},{"issue":"2","key":"2026071409581209700_bib25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1542\/peds.76.2.286","article-title":"Healing rates of treated and untreated bone lesions in histiocytosis X","volume":"76","author":"Womer","year":"1985","journal-title":"Pediatrics"},{"issue":"3","key":"2026071409581209700_bib26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11999-011-2162-x","article-title":"Does adjunctive chemotherapy reduce remission rates compared to cortisone alone in unifocal or multifocal histiocytosis of bone?","volume":"470","author":"Baptista","year":"2012","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"2026071409581209700_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/bjh.13955","article-title":"Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy","volume":"173","author":"Arico","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2026071409581209700_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200107193450318","article-title":"Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis","volume":"345","author":"Arzoo","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071409581209700_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2796.1989.tb00038.x","article-title":"Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone","volume":"225","author":"Elomaa","year":"1989","journal-title":"J Intern Med"},{"issue":"1","key":"2026071409581209700_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00043426-200101000-00013","article-title":"Treatment of Langerhans cell histiocytosis with pamidronate","volume":"23","author":"Farran","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"2026071409581209700_bib31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1359\/jbmr.2002.17.11.1926","article-title":"Bisphosphonate induces remission of refractory osteolysis in Langerhans cell histiocytosis","volume":"17","author":"Kamizono","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071409581209700_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/pbc.22703","article-title":"Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan","volume":"56","author":"Morimoto","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2026071409581209700_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-911X(199904)32:4<247::AID-MPO1>3.0.CO;2-J","article-title":"Use of indomethacin in Langerhans cell histiocytosis","volume":"32","author":"Munn","year":"1999","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"2026071409581209700_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pbc.21668","article-title":"Clofarabine in refractory Langerhans cell histiocytosis","volume":"51","author":"Rodriguez-Galindo","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026071409581209700_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12185-018-2444-0","article-title":"Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study","volume":"108","author":"Morimoto","year":"2018","journal-title":"Int J Hematol"},{"issue":"1","key":"2026071409581209700_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12185-023-03568-0","article-title":"Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study","volume":"118","author":"Morimoto","year":"2023","journal-title":"Int J Hematol"},{"issue":"5","key":"2026071409581209700_bib37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.05.002","article-title":"Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry","volume":"153","author":"Minkov","year":"2008","journal-title":"J Pediatr"},{"issue":"7","key":"2026071409581209700_bib38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/pbc.21145","article-title":"Reactivation and risk of sequelae in Langerhans cell histiocytosis","volume":"48","author":"Pollono","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026071409581209700_bib39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bjh.18583","article-title":"Relapses of multisystem\/multifocal bone Langerhans cell histiocytosis in paediatric patients: data analysis from the JLSG-96\/02 study","volume":"200","author":"Sakamoto","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4776\/2531502\/blooda_adv-2026-020075-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4776\/2531502\/blooda_adv-2026-020075-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:58:23Z","timestamp":1784037503000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4776\/568272\/Disease-extent-not-lesion-location-determines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020075","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,7,1]]}}}